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The human genome is replete with regulatory elements such as promoters, enhancers and insulators. Recent findings have highlighted the impact of spatial genome organization in 
governing the physical proximity of these elements for the precise 
control of gene expression1–3. Genome organization is a multistep 
process that involves compacting chromatin into nucleosomes, 
chromatin fibers, compartments and chromosome territories3,4. 
Multiple lines of evidence have suggested that, at the sub-megabase 
level, the genome is organized in distinct regions of highly self-inter-
acting chromatin called TADs5–7. An important function of TADs is 
to restrict the interactions of regulatory elements to genes within 
the same TAD, while insulating them from interactions with neigh-
boring domains3,4. Further evidence from our laboratory suggests 
that super-enhancers, which often regulate key genes determining 
cellular identity or driving tumorigenesis8,9, are frequently insu-
lated by and co-duplicated with strong TAD boundaries in cancer10. 
TAD boundaries are enriched in binding of structural proteins 
(CTCF and cohesin)11. Cohesin-mediated, convergently oriented 
CTCF–CTCF structural loops are essential for the organization of 
the genome into TADs12–14. Abrogation of CTCF binding or inver-
sion of its orientation in boundary regions can change TAD struc-
ture and reconfigure enhancer–promoter interactions15, leading to 
aberrant gene activation and developmental defects1,16.
In light of these reports, understanding how chromatin orga-
nization contributes to cancer pathogenesis remains largely unex-
plored, barring a few examples2,17,18. Here, by using T-ALL as a 
model19,20, we investigated potential reorganization of global chro-
matin architecture in primary T-ALL samples, T-ALL cell lines and 
healthy peripheral T cells. Our analysis identified recurrent struc-
tural differences at TAD boundaries and significant alterations in 
intra-TAD chromatin interactions that mirrored differences in gene 
expression. Both types of alterations affected effectors of oncogenic 
NOTCH1 signaling. As a principal example, we identified a recur-
rent TAD boundary change in T-ALL within the locus of a key 
driver of T cell leukemogenesis, MYC, which facilitates long-range 
interactions of the MYC promoter with a previously characterized 
NOTCH-bound super-enhancer. Furthermore, highlighting a direct 
role for NOTCH1 in organizing chromatin architecture, inhibi-
tion of NOTCH1 signaling using gamma-secretase inhibitors (γSI) 
reduced chromatin looping in a number of enhancer–promoter 
pairs that are sensitive to γSI treatment (called ‘dynamic NOTCH1’ 
sites21). Loss of chromatin interactions between enhancer–promoter 
loops was associated with a reduction in acetylation at histone H3 
lysine 27 (H3K27ac) at the respective enhancer. However, a subset 
of enhancer–promoter loops, including the MYC–super-enhancer 
loop, retained their interactions with target promoters after γSI 
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Differences in three-dimensional (3D) chromatin architecture can influence the integrity of topologically associating domains 
(TADs) and rewire specific enhancer–promoter interactions, impacting gene expression and leading to human disease. Here 
we investigate the 3D chromatin architecture in T cell acute lymphoblastic leukemia (T-ALL) by using primary human leuke-
mia specimens and examine the dynamic responses of this architecture to pharmacological agents. Systematic integration of 
matched in situ Hi-C, RNA-seq and CTCF ChIP–seq datasets revealed widespread differences in intra-TAD chromatin interac-
tions and TAD boundary insulation in T-ALL. Our studies identify and focus on a TAD ‘fusion’ event associated with absence of 
CTCF-mediated insulation, enabling direct interactions between the MYC promoter and a distal super-enhancer. Moreover, our 
data also demonstrate that small-molecule inhibitors targeting either oncogenic signal transduction or epigenetic regulation 
can alter specific 3D interactions found in leukemia. Overall, our study highlights the impact, complexity and dynamic nature of 
3D chromatin architecture in human acute leukemia.
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Fig. 1 | In situ Hi-C analysis identifies genome-wide 3D chromatin differences between normal T cells and T-ALL subtypes. a, Schematic showing the 
overall study design. b, PCA of the hic-ratio insulation scores for each Hi-C dataset (n = 13) identifies three distinct clusters. Clustering was performed by 
using the R package Mclust, with the EII and VII models showing optimal separation when using three clusters. c, Heat map representation of RNA-seq 
results for clusters 2 and 3 separated by T-ALL and ETP-ALL gene signature (rows). Gene signatures were derived from the RNA-seq results in refs. 24,26,30. 
The heat map shows the row z score of FPKM normalized read counts determined by using the edgeR function rpkm. d, PCA of hic-ratio insulation scores 
as in b (n = 13); samples are colored by cell type assignment determined with the help of RNA-seq data. e, Compartment analysis using c score on all Hi-C 
datasets (n = 13). Different categories of disease-specific and common compartment switches were identified by unpaired two-sided t tests on c scores 
from comparisons between T-ALL, ETP-ALL and T cells (P < 0.1).
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treatment, despite being bound by NOTCH1. In exploring puta-
tive cofactors maintaining long-range interactions, we identified 
CDK7 binding to be enriched in γSI-insensitive chromatin contacts. 
Pharmacological inhibition of CDK7 using the covalent inhibi-
tor THZ1 significantly reduced MYC promoter contacts with the 
super-enhancer, underlining the complexity of the factors regulat-
ing 3D architecture. Taken together, our findings provide deeper 
insight into how 3D chromatin architecture can affect the regula-
tory landscape of oncogenes in human leukemia and suggest that 
some of the changes can be inhibited by targeted drug treatments.
results
Widespread changes in 3D chromatin landscape in human 
T-ALL. T-ALL accounts for approximately 25% of ALL cases22 and is 
characterized by activating mutations in NOTCH1 in approximately 
50% of patients23,24. On the basis of gene expression signatures and 
immunophenotyping, T-ALL is classified into two subtypes, includ-
ing ‘canonical’ T-ALL, characterized by frequent NOTCH1 muta-
tions with an immature T cell phenotype, and the early T-lineage 
progenitor (ETP) leukemia subtype, frequently expressing stem cell 
and myeloid cell-surface markers25,26. Although the genetic drivers 
of T-ALL are well characterized, it has not been investigated whether 
malignant transformation of immature T  cells is associated with 
widespread changes in chromatin architecture. Herein, to broadly 
assess the global chromatin architecture in T-ALL, we performed 
in  situ Hi-C in eight primary peripheral blood T-ALL samples, 
T-ALL cell lines (CUTLL1 (ref. 27) and Jurkat28 cells) and mature 
peripheral blood T cells from three healthy donors. We integrated 
these datasets with CTCF binding, RNA expression and enhancer 
activity (Fig. 1a). The Hi-C data, processed by our HiC-bench plat-
form29, showed alignment rates with a high percentage of usable 
long-range read pairs (Extended Data Fig. 1a and Supplementary 
Table 1). Principal-component analysis (PCA) of genome-wide 
‘hic-ratio’ insulation scores (from the HiC-bench platform), repre-
senting the insulation capacity of each genome-wide bin, indicated 
three distinct clusters of samples clearly separated by the first two 
components (Fig. 1b). Cluster 1 samples were identified as mature 
peripheral T cells and were separated from T-ALL samples (clus-
ters 2 and 3) by the first principal component. To discern the iden-
tity of clusters 2 and 3, we interrogated the expression patterns of 
these samples by using gene signatures for canonical T-ALL and 
ETP-ALL24,26,30. Among the T-ALL samples, the four T-ALL samples 
grouped in cluster 3 were identified to share a characteristic gene 
signature of the ETP-ALL subtype (Fig. 1c). The expression of clus-
ter 2 samples overlapped with that of canonical T-ALL, with a single 
exception (Supplementary Note). Thus, assignment of canonical 
T-ALL and ETP-ALL using gene expression information explains 
the variation in Hi-C insulation scores between clusters 2 and 3 
(Fig. 1d). Additionally, we calculated matrix-wide stratum-adjusted 
correlation coefficients by using HiCRep31 between the Hi-C con-
tact matrices for all pairwise comparisons. We observed higher 
correlation among the T cells and among the two T-ALL subtypes 
(Extended Data Fig. 1b), further supporting genome-wide varia-
tions in 3D architecture between the T cells and T-ALL samples, but 
also between the two distinct T-ALL subtypes. To better characterize 
differences in 3D architecture that underlie this separation, we first 
examined compartmentalization of the genome between the three 
clusters of Hi-C samples (Supplementary Note). Compartment shifts 
both common and unique to the T-ALL subtypes were identified 
relative to T cells (Extended Data Fig. 1c). We also identified strong 
correlations of compartment shifts with expression changes (Fig. 1e, 
Extended Data Fig. 1d,e and Supplementary Table 3). Collectively, 
these data show that differences in 3D architecture occur between 
T cells and T-ALL and also between subtypes of human T-ALL.
Intra-TAD activity differences affect downstream effectors 
of T-ALL pathogenesis. We then focused on all common TADs 
between T cells and T-ALL found within the transcriptionally active 
A compartment in either T cells or T-ALL. We defined ‘intra-TAD 
activity’ as the average of the normalized interaction scores for all 
interactions within the particular TAD. Differences in intra-TAD 
activity were determined by comparing the fold change in aver-
age intra-TAD activity between all T  cell samples and the four 
primary canonical T-ALL samples (Supplementary Methods). 
Comparison of intra-TAD activity between canonical T-ALL sam-
ples and controls identified several statistically significant increases 
and decreases (Fig. 2a and Supplementary Table 4; false-discovery 
rate (FDR) < 0.1 and log2 (fold change) >0.58 or <−0.58), whereas 
comparison between two independent T  cell samples identified 
only a few changes when applying the same thresholds (Fig. 2b). 
Furthermore, the TAD activity changes were highly similar across 
primary canonical T-ALL samples and T-ALL cell lines (Fig. 2c), 
with some expected heterogeneity. Only ~16–18% of the identified 
intra-TAD activity changes had concomitant compartment shifts, 
with the majority falling in the A compartment in both T cells and 
T-ALL samples (Supplementary Fig. 1a). Additionally, TAD activity 
Fig. 2 | Intra-TAD activity changes affect downstream effectors of T-ALL pathogenesis. a, Volcano plot showing differential intra-TAD activity for 
comparisons of T cells versus canonical T-ALL (all TADs, n = 1,027). Statistical evaluation was performed by paired two-sided t test pairing each 
interaction bin per TAD between the averages of T cells and canonical T-ALL, followed by multiple-testing correction. b, Volcano plot of the same analysis 
as in a between two independent T cell Hi-C samples (all TADs, n = 1,027). c, Heat map showing average per-sample intra-TAD activity in T-ALL and 
T cells normalized by the average intra-TAD activity across all three T cell samples. Rows show differentially active and stable TADs as highlighted in a. 
d, Integration of CTCF binding with the TAD boundary categories from a. All CTCF binding peaks from surrounding TAD boundaries were aggregated, 
and the log2 (fold change) in CTCF signal between T-ALL and T cells is shown. Significant differences were calculated by unpaired one-sided t test 
comparing TADs with decreased or increased intra-TAD activity to stable TADs. e, Integration of RNA expression (FPKM > 1) within TADs with decreased 
or increased intra-TAD activity. For each gene, the log2 (fold change) in expression between T-ALL and T cells from RNA-seq data is shown. Significant 
differences were calculated by unpaired one-sided t test comparing genes from TADs with decreased or increased intra-TAD activity to genes from stable 
TADs. f, Super-enhancer integration with differentially active TADs. Enrichment score was calculated as the observed overlap between super-enhancers 
and differentially active versus stable TADs over expected background. Statistical enrichment was calculated by two-sided Fisher’s exact test. g, Number 
of dynamic NOTCH1-binding sites per 1 Mb within TADs of decreased, stable or increased intra-TAD activity as defined in a. Significant differences for 
TADs with increased or decreased activity versus stable TADs were identified by unpaired two-sided t test. h, The top row shows Hi-C interaction heat 
maps. The bottom row shows heat maps of per-bin log2 (fold change) in interactions when compared to the T cell 1 sample. i, H3K27ac and NOTCH1  
ChIP–seq tracks for the APCDD1 locus, with data shown as fold enrichment over input. The gray area indicates TAD containing APCDD1. Number of 
replicates: T cells H3K27ac, n = 2; CUTLL1 H3K27ac, n = 2; CUTLL1 NOTCH1, n = 1. j, Quantification of intra-TAD activity (left; area as highlighted in i) and 
expression of APCDD1 (right). Statistical evaluation for intra-TAD activity was performed by paired two-sided t test comparing the average per interaction 
bin for the APCDD1 TAD between T cells (n = 3) and T-ALL (n = 6), followed by multiple-testing correction. APCDD1 expression was determined by RNA-
seq and is shown as the log2 (FPKM) for T cell (n = 13) and T-ALL (n = 6) samples; normalization and statistical evaluation were performed with edgeR 
followed by multiple-testing correction. Box-plot information can be found in the Source Data.
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changes were minimally impacted by genomic alterations such as 
translocations and copy number variants (Supplementary Note).
To further characterize differential intra-TAD activity between 
T-ALL and T cells, we integrated CTCF binding (chromatin immu-
noprecipitation and sequencing, ChIP–seq) with our Hi-C datasets. 
Interestingly, changes in intra-TAD activity strongly correlated with 
CTCF binding changes at the boundaries of differentially active 
TADs. Stronger insulation by CTCF was associated with stronger 
intra-TAD activity (Fig. 2d). Next, to investigate whether CTCF-
binding-associated differences in intra-TAD interactions were 
also associated with changes in gene expression, we performed 
differential expression analysis of all expressed genes (FPKM > 1, 
canonical T-ALL versus T cells) within differentially active TADs. 
Increased chromatin interactions in T-ALL significantly associated 
with positive fold changes in gene expression, whereas decreased 
intra-TAD activity in T-ALL associated with negative fold changes 
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in gene expression relative to expression changes within stable 
TADs (Fig. 2e). We then overlapped intra-TAD activity results with 
cell-type-specific super-enhancer occurrence in T-ALL and T cells 
(Supplementary Note). We found significant enrichment of T-ALL-
specific super-enhancers within TADs of increased activity in T-ALL 
and vice versa (Fig. 2f). Additionally, TADs with higher activity in 
T-ALL were significantly enriched in dynamic NOTCH1-binding 
sites21, whereas TADs with lower activity in T-ALL were signifi-
cantly depleted of dynamic NOTCH1-binding sites in comparison 
to stably active TADs (Fig. 2g). Taken together, these results dem-
onstrate widespread changes in intra-TAD activity in T-ALL when 
compared to peripheral T cells that are associated with CTCF bind-
ing, mRNA expression and super-enhancer activity. Furthermore, 
we identified single-nucleotide variants to have minimal impact on 
the observed differential CTCF binding (Supplementary Fig. 1f).
Our comparison of changes in TAD activity and super-enhancer 
firing suggests that 3D chromosomal changes potentially occur in loci 
important for T-ALL pathogenesis, including loci with NOTCH1 tar-
get genes highly expressed in samples from individuals with T-ALL. 
One such gene is APCDD1 (adenomatous polyposis coli downregu-
lated 1), encoding a membrane-bound glycoprotein overexpressed in 
samples from individuals with T-ALL. APCDD1 is a NOTCH1 target 
gene significantly downregulated following inhibition of NOTCH1 
signaling by γSI (dynamic NOTCH1 target)21. Our Hi-C data showed 
APCDD1 to be present in a highly active TAD in T-ALL (Fig. 2h,j), 
which was common among all the T-ALL samples and displayed 
concomitant enhancer elements in T-ALL (Fig. 2i). The gain of 
TAD activity also correlated with increased expression of APCDD1 
in T-ALL samples relative to T cells (Fig. 2j). Another example of a 
T-ALL-specific increase in intra-TAD activity, enhancer activity and 
gene expression was the Ikaros family gene IKZF2 (Helios), previ-
ously found to be involved in the regulation of T cell differentiation32. 
We identified a T-ALL-specific super-enhancer within the same 
TAD, as well as significantly increased gene expression in T-ALL as 
compared to T cells (Extended Data Fig. 2a–c). In contrast, among 
the TADs that lost activity in T-ALL, we identified CYLD, encod-
ing a deubiquitinating enzyme that represses NF-κB signaling and is 
known as a T-ALL tumor suppressor33,34. We found significant reduc-
tion of interactions in the TAD that harbors CYLD in all profiled 
T-ALL samples (Extended Data Fig. 2d,e). The reduced TAD activity 
also correlated with reduced expression in T-ALL samples (Extended 
Data Fig. 2f). Extending our analysis, we also identified subtype-spe-
cific differences in intra-TAD activity between the canonical T-ALL 
and ETP-ALL samples (Supplementary Note).
Identification of recurrent TAD insulation changes in T-ALL. 
Following our intra-TAD activity analysis, we investigated TAD 
boundary changes between normal T  cells and T-ALL. A TAD 
boundary ‘loss’ was defined as an increase in inter-TAD interactions 
between two adjacent TADs leading to a TAD ‘fusion’. Conversely, a 
TAD boundary ‘gain’ was defined as a decrease in inter-TAD inter-
actions between two adjacent TADs leading to a TAD ‘separation’ 
(Fig. 3a and Supplementary Methods). Global analysis of altera-
tions in TAD insulation revealed TAD boundary changes in both 
directions (Fig. 3a), whereas pairwise comparison of T cells from 
independent donors identified only a few TAD boundary altera-
tions. However, considering all such insulation changes between 
the T cell samples as false positives, we estimated an approximate 
FDR of 9.58% for TAD boundary changes in T-ALL as compared 
to T cells (Fig. 3b). Furthermore, about 53–58% of TAD boundary 
differences were accompanied by simultaneous changes in CTCF 
binding within the respective boundaries (Fig. 3c,d). For an inde-
pendent validation of these findings, we calculated the hic-ratio 
insulation score for all TAD boundary alterations found in compari-
son of T-ALL samples and T cells. The hic-ratio insulation score was 
on average increased and decreased for TAD boundary gains and 
losses, respectively, across all T-ALL samples (Fig. 3e,f). Very few 
of the observed TAD insulation changes overlapped with genomic 
alterations such as deletions or insertions (Supplementary Note).
CTCF-mediated TAD insulation defines accessibility of MYC 
promoter–super-enhancer looping. MYC expression is signifi-
cantly upregulated in T-ALL, and MYC is one of the main onco-
genes activated downstream of NOTCH1 signaling35,36. Intriguingly, 
we identified a recurrent TAD fusion in the MYC locus in all T-ALL 
samples as compared to T cells (Fig. 4a), which was associated with 
a strong increase in inter-TAD interactions in T-ALL. Furthermore, 
the TAD fusion was associated with CTCF changes. We confirmed 
CTCF binding at the TAD boundary in T  cells and an almost 
complete absence of binding across the T-ALL samples (Fig. 4b 
and Extended Data Fig. 5a). The absence of CTCF binding was 
due neither to genomic mutations (Extended Data Fig. 5b) nor 
to DNA hypermethylation within or adjacent to the CTCF-binding 
site in T-ALL (data not shown). Furthermore, 5-azacytidine treat-
ment leading to global DNA demethylation led to no restoration of 
CTCF binding in CUTLL1 cells (Extended Data Fig. 5c). Instead, 
assay for transposase-accessible chromatin using sequencing 
(ATAC–seq) data indicated significantly reduced chromatin acces-
sibility of the CTCF-binding site in T-ALL (Fig. 4b and Extended 
Data Fig. 5d).
In T-ALL, MYC transcription is controlled by distant 3D inter-
actions with a long stretch of enhancers, including the previously 
characterized NOTCH1-bound N-Me/NDME element37,38 (Fig. 4b). 
As a result of the TAD fusion, the MYC promoter and the 
Fig. 4 | CTCF-mediated TAD insulation defines the accessibility of MYC promoter–super-enhancer looping. a, The top row shows Hi-C interaction heat 
maps, with the MYC locus and super-enhancers indicated. The second row shows heat maps of per-bin log2 (fold change) in interactions when compared 
to the T cell 1 sample. b, CTCF and H3K27ac ChIP–seq tracks for the MYC locus. CTCF orientation is shown for canonical CTCF binding motifs derived 
from PWMScan61 (database JASPAR CORE vertebrates; filtered by P < 1 × 10−5; n = 143,164 total CTCF binding motifs). ChIP–seq and ATAC–seq tracks 
show fold enrichment over input where applicable and counts per million reads otherwise. The gray area indicates super-enhancer elements. Number of 
replicates: T cells CTCF, n = 2; T-ALL 1 CTCF, n = 2; T-ALL 3 CTCF, n = 1; CUTLL1 CTCF, n = 5; Jurkat CTCF, n = 2; T cells H3K27ac, n = 2; CUTLL1 H3K27ac, 
n = 2; CUTLL1 NOTCH1, n = 1; T cells ATAC–seq, n = 6; Jurkat ATAC–seq, n = 3. c, 4C–seq using the MYC promoter as the viewpoint. The positive y axis 
shows interactions with the MYC promoter viewpoint as normalized read counts, and the negative y axis shows the significance of differential interactions 
between T cells and CUTLL1 cells as the log10 (P value) derived by using the edgeR function glmQLFTest. Tracks below are H3K27ac ChIP–seq tracks 
for T cells and CUTLL1 cells shown as fold enrichment over input. The gray areas indicate super-enhancer elements. Number of replicates: T cells 4C, 
n = 2; CUTLL1 4C, n = 5; T cells H3K27ac, n = 2; CUTLL1 H3K27ac, n = 2. d, MYC expression shown as log2 (FPKM) for T cells (n = 13) and T-ALL (n = 6). 
Statistical evaluation was performed by two-sided edgeR analysis with glmQLFTest followed by multiple-testing correction. e, Left, distance between 
the MYC promoter and the center enhancer element (MYC-CCE) measured by DNA FISH analysis. The statistical difference between distributions of 
probe distances was calculated by two-sample one-sided Kolmogorov–Smirnov test following the hypothesis of increased probe distance in T cells 
when compared to T-ALL. Error bars, s.d.; the center values correspond to the median. Probe pairs: T cells, 993; CUTLL1, 2,001. Median distance: T cells, 
412.84 μm; CUTLL1, 264.28 μm. Right, representative images of MYC promoter and MYC-CEE probes in T cells and CUTLL1. Box-plot information can be 
found in the Source Data.
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super-enhancer, separated by strong insulation in T  cells, were 
in spatial proximity within the same TAD in leukemic samples 
(Fig. 4a,b). Circularized chromatin conformation capture and 
sequencing (4C–seq) analysis using the MYC promoter as the 
viewpoint confirmed the interaction between the MYC promoter 
and the super-enhancer in primary T-ALL samples and CUTLL1 
cells, whereas in untransformed T  cells no such interaction was 
observed (Fig. 4c and Extended Data Fig. 6a). Interestingly, our 
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analysis showed that the strongest and most significant interactions 
specifically overlapped with H3K27ac ChIP–seq peaks throughout 
the entire super-enhancer, including an uncharacterized putative 
center enhancer element (from this point on referred to as MYC-
CEE) and the recently identified BDME/BENC enhancer (Fig. 4c 
and Extended Data Fig. 6a)39,40. In agreement with our 3D chro-
mosomal interaction data, MYC was overexpressed in our cohort 
of samples from individuals with T-ALL as compared to normal 
T  cells (Fig. 4d). We independently validated the interaction by 
using 3D FISH with probes targeting the MYC promoter and MYC-
CEE. Inter-probe distance was significantly higher in T cells than in 
T-ALL (CUTLL1 cell line), in line with the 4C–seq results (Fig. 4e). 
Additionally, disruption of CTCF binding by CRISPR-induced 
mutation in normal T  cells significantly reduced interactions 
between the MYC promoter and the CTCF-bound TAD boundary 
region in edited T cells as compared to wild-type T cells (Extended 
Data Fig. 7a–e and Supplementary Note).
Pharmacological NOTCH1 inhibition leads to a decrease in 3D 
interactions in a subset of NOTCH1-regulated loci. Our analysis 
revealed widespread changes in global TAD structure and intra-
TAD activity affecting important genes in T-ALL. However, whether 
oncogenic drivers, such as NOTCH1, have a direct role in these 
changes and whether their inhibition can reverse these changes 
remain open questions. To address this, we performed in situ Hi-C 
in CUTLL1 cells treated with γSI for 72 h (refs. 21,35). γSI selectively 
inhibits NOTCH1 signaling and has strong antileukemic effects36,41. 
Hi-C analysis after γSI treatment did not reveal any significant 
changes in intra-TAD activity (Extended Data Fig. 8a) or reversal 
of changes in TAD boundary insulation (Extended Data Fig. 8b). 
Moreover, it was previously shown that about 90% of NOTCH1-
binding sites that are sensitive to γSI treatment (dynamic NOTCH1 
sites) are located in putative enhancers. These dynamic NOTCH1-
occupied enhancers also show significant changes in H3K27ac 
signal after NOTCH1 inhibition21. We investigated whether chro-
matin interactions between such enhancers and target promoters 
were altered after γSI treatment. We first profiled H3K27ac after 
γSI treatment and categorized all non-promoter H3K27ac peaks as 
either stable peaks or peaks that displayed a significant reduction 
or increase in H3K27ac signal (Fig. 5a). As previously observed, 
the H3K27ac peaks with reduced signal after γSI treatment were 
significantly enriched for dynamic NOTCH1 binding as compared 
to stable peaks and those with increased H3K27ac signal21 (Fig. 5b). 
Next, to connect NOTCH1 inhibition, changes in H3K27ac and 3D 
looping, we used Hi-C data after γSI treatment to quantify changes in 
chromatin interactions of H3K27ac-enriched chromatin loops identi-
fied by H3K27ac HiChIP in CUTLL1 cells42. Our HiChIP data showed 
enrichment of enhancer–promoter interactions, as demonstrated by 
virtual 4C analysis using the MYC promoter as the virtual viewpoint 
(Extended Data Fig. 8c). Dynamic NOTCH1-bound enhancers 
with reduced H3K27ac levels after γSI treatment showed the stron-
gest loss of chromatin interactions with connected genes (Fig. 5c). 
Interestingly, dynamic NOTCH1-bound enhancers with stable 
H3K27ac signal remained in stable contact with nearby promoters. 
To correlate changes in chromatin interactions with the dynamics 
of NOTCH1-dependent transcription, we performed global run-on 
sequencing (GRO-seq)43 to measure nascent transcription after γSI 
treatment and after inhibitor ‘washout’. Interestingly, the enhancer–
promoter contacts most sensitive to γSI treatment included genes 
that showed significant response in transcription to NOTCH1 inhi-
bition and after γSI washout (Fig. 5d).
To further validate changes among NOTCH1-sensitive 
enhancer–promoter interactions, we performed 4C–seq on two 
previously characterized NOTCH1 T-ALL targets, LUNAR1 and 
APCDD1. LUNAR1 is a long noncoding RNA that we have previ-
ously identified as a cis regulator of expression of the neighbor-
ing IGF1R gene, achieved by looping of the LUNAR1 promoter 
with an IGF1R intronic enhancer44,45. 4C–seq using the LUNAR1 
promoter as the viewpoint identified strong interactions with the 
IGF1R enhancer. However, the interactions decreased significantly 
after NOTCH1 inhibition (Fig. 5e and Extended Data Fig. 8d), 
which correlated with reduced H3K27ac signal at the enhancer 
and decreased expression of LUNAR1 (Fig. 5e and Extended Data 
Fig. 8d). Similarly, by using 4C–seq with an APCDD1 enhancer as 
the viewpoint, which displayed dynamic NOTCH1 binding and 
reduced H3K27ac signal upon NOTCH1 inhibition, we identified 
decreased interaction between the enhancer and the promoter of 
APCDD1 after γSI treatment. These changes correlated with reduced 
expression of APCDD1 (Fig. 5f and Extended Data Fig. 8e). These 
results suggest that pharmacological NOTCH1 inhibition can affect 
the activity (as defined by H3K27ac levels) of dynamic NOTCH1-
bound enhancers and that 3D interactions with such enhancers are 
significantly diminished. However, a subset of NOTCH1-regulated 
loci had neither significant H3K27ac loss nor reduced chromatin 
interactions after γSI treatment, including the previously described 
MYC enhancer–promoter interaction and looping of a dynamic 
Fig. 5 | NOTCH1 inhibition affects enhancer–promoter looping, specifically of NOTCH1-dependent enhancers. a, H3K27ac occupancy in CUTLL1 
cells with and without the NOTCH1 inhibitor γSI. Groups consisted of stable (middle, white; n = 2,949), increased (top, purple; n = 125) and reduced 
(bottom, light blue; n = 243) non-promoter H3K27ac signal. The heat map shows the H3K27ac signal as fold enrichment over input, and line plots depict 
quantification of H3K27ac signal (both created with DeepTools62). Differential analysis was performed with the R package DiffBind using the edgeR 
method, and differential peaks were selected by FDR < 0.05 and log2 (fold change) >1.0 or <−1.0. Number of replicates: CUTLL1 DMSO, n = 4; CUTLL1 
γSI, n = 2. b, Left, overlap of constant, increased and reduced H3K27ac peaks with previously defined NOTCH1 dynamic sites21. Right, quantification 
of H3K27ac signal shown as fold enrichment over input for peaks with reduced H3K27ac signal and dynamic NOTCH1 binding (n = 76). Statistical 
evaluation was performed by two-sided Fisher’s test against all noncoding H3K27ac peaks overlapping dynamic NOTCH1 binding. c, Changes in chromatin 
interactions upon γSI treatment between non-promoter H3K27ac peaks defined in a and b and connected gene promoters, shown as log2 (fold change) in 
average normalized interaction score (average of n = 2 biological replicates). Each dot represents an enhancer–promoter interaction defined by H3K27ac 
HiChIP in CUTLL1 cells. The significance of shifts in interaction strength in comparison to the enhancer–promoter loops of stable enhancers was calculated 
by unpaired one-sided t test, following the hypothesis of a positive correlation between enhancer activity and promoter looping. d, Gene expression upon 
γSI treatment for all genes defined in c, shown as the log2 (fold change) in FPKM calculated from GRO-seq data. The significance of differences compared 
to genes associated with stable H3K27ac signal was calculated by unpaired one-sided t test, following the hypothesis of a positive correlation between 
enhancer–promoter looping and gene expression. e,f, 4C–seq using the LUNAR1 promoter (e) and the APCDD1 enhancer (f) as the viewpoint. The positive 
y axis shows interactions with the viewpoint as normalized read counts, and the negative y axis shows the significance of differential interactions between 
untreated and γSI-treated CUTLL1 cells as the log10 (P value) calculated with the edgeR function glmQLFTest. Tracks below show H3K27ac and NOTCH1 
ChIP–seq and GRO-seq (positive strand only) as fold enrichment over input where applicable and counts per million otherwise. The gray areas indicate 
LUNAR1 enhancer (e) or APCDD1 promoter (f). Number of replicates: CUTLL1 DMSO 4C LUNAR1, n = 2; CUTLL1 γSI 4C LUNAR1, n = 2; CUTLL1 DMSO 
4C APCDD1, n = 2; CUTLL1 γSI 4C APCDD1, n = 2; CUTLL1 DMSO H3K27ac, n = 2; CUTLL1 γSI H3K27ac, n = 2; CUTLL1 DMSO NOTCH1, n = 1; CUTLL1 γSI 
NOTCH1, n = 1; CUTLL1 DMSO GRO-seq, n = 2; CUTLL1 γSI GRO-seq, n = 2. Box-plot information can be found in the Source Data.
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NOTCH1-bound enhancer to the IKZF2 promoter (Extended 
Data Figs. 8f,g and 9, and Supplementary Note). This suggests that 
NOTCH1 binding is critical for maintaining enhancer–promoter 
contacts in only a subset of loops and additional chromatin regula-
tors may have a role in maintaining the chromatin interactions of 
γSI-insensitive loops.
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CDK7 inhibition targets γSI-insensitive enhancer–promoter 
loops. To further understand the differential sensitivity of dynamic 
NOTCH1-bound enhancers, we performed a differential binding 
analysis using LOLA and its associated LOLA database46 compar-
ing the γSI-sensitive and γSI-insensitive enhancers. Among the 
chromatin regulators and transcription factors available for T-ALL, 
we found cyclin-dependent kinase 7 (CDK7) binding to be signifi-
cantly enriched in γSI-insensitive enhancers as compared to γSI-
sensitive enhancers (Fig. 6a). To globally assess the role of CDK7 
binding in the maintenance of γSI-insensitive enhancer–promoter 
loops, we performed Hi-C in CUTLL1 cells treated with the CDK7 
inhibitor THZ1, which was previously demonstrated to have strong 
antileukemic activity47. As before, we profiled H3K27ac levels after 
THZ1 treatment by ChIP–seq and categorized all non-promoter 
H3K27ac peaks as peaks with stable, significantly reduced (THZ1-
lost enhancers) or significantly increased (THZ1-gained enhancers) 
H3K27ac signal (Fig. 6b). Globally, as previously observed in γSI 
treatment, enhancers with significant reduction in H3K27ac signal 
had a correlative reduction in long-range chromatin interactions 
to target promoters, whereas THZ1-insensitive enhancers neither 
gained nor lost chromatin interactions on average (Fig. 6c).
To further test the role of CDK7 in maintaining loops, we per-
formed 4C–seq after THZ1 treatment in the previously identified 
γSI-insensitive MYC and IKZF2 loci. We observed a significant 
decrease in the interaction of both N-Me/NDME and MYC-CEE 
with the MYC promoter after treatment with the CDK7 inhibitor 
(Fig. 6d and Extended Data Fig. 10a). These changes were accompa-
nied by a significant decrease in H3K27ac signal and MYC expres-
sion (Fig. 6d and Extended Data Fig. 10a,b). Finally, no significant 
gain in the binding of CTCF to the TAD boundary was observed, 
suggesting that the described loss of enhancer–promoter interaction 
occurs independently of CTCF binding (Extended Data Fig. 10c). 
Additionally, DNA FISH analysis confirmed a significant increase 
in 3D distance between MYC promoter and MYC-CEE probes after 
THZ1 treatment (Extended Data Fig. 10d). The effect of CDK7 on 
DNA looping was further confirmed in another T-ALL cell line and 
locus (Supplementary Note, Fig. 6e and Extended Data Fig. 10e–
g). Overall, we demonstrate that targeting a transcription factor 
(NOTCH1) affects only a subset of 3D enhancer–promoter interac-
tions associated with dynamic NOTCH1 binding. Additional factors 
such as CDK7 can maintain contacts in a subset of γSI-insensitive 
enhancers in T-ALL. Furthermore, changes in H3K27ac levels 
emerge as a reliable indicator of chromatin interaction dynamics 
after drug treatments.
Discussion
Despite the intense focus on the regulatory role of TADs in human 
disease, it remains largely unexplored whether TAD boundary 
or intra-TAD activity changes are important for tumor initiation 
or maintenance. Indeed, aberrant activation of cancer drivers by 
enhancer hijacking remains the primary known mechanism linking 
3D structural changes to oncogenic transformation2,3,48,49. Our studies 
further these findings by using human T-ALL as a model. They high-
light the underlying complexity of factors regulating the 3D landscape 
in human leukemia, with notable variations among different leuke-
mia subtypes, and suggest that drugs with reported antileukemic 
activity partially reverse 3D interactions in specific loci, potentially 
accounting for the antileukemogenic effects of these drugs.
Frequent loss of TAD boundary insulation has previously been 
observed in human cancer, including in T-ALL49. In line with these 
findings, we identify here a TAD boundary change within the MYC 
locus that is associated with increased enhancer–promoter interac-
tions. MYC is an important downstream target of NOTCH1 that 
activates anabolic pathways to sustain the proliferation induced by 
constitutive NOTCH1 activation35,36. Our observations suggest that 
MYC upregulation in T-ALL relative to mature T cells is associated 
with differences in local chromatin architecture. At this point, it is 
not clear what regulates CTCF binding within the TAD boundary in 
T-ALL and T cells, although our preliminary studies have excluded 
a role for DNA methylation and somatic mutations in the CTCF 
motif. Interestingly, by using ATAC–seq, we found that the CTCF 
site was accessible in T  cells but displayed greatly reduced acces-
sibility in T-ALL, suggesting differential chromatin accessibility as 
a potential mechanism of regulating CTCF binding. In support of 
this hypothesis, a recent report identified chromatin accessibility 
as correlating with CTCF binding during the transition from inter-
phase to prometaphase50. In addition to the lost CTCF boundary 
in T-ALL, we also observed an increase in CTCF binding with the 
same orientation (facing into the TAD and toward MYC) down-
stream of the super-enhancer. Such clusters of CTCF surrounding 
super-enhancers have recently been described as super-anchors 
that ensure super-enhancer-mediated regulation of nearby genes51. 
Further studies of the regulatory mechanism underlying CTCF 
binding and chromatin accessibility in the MYC locus could provide 
alternate strategies to decrease MYC expression in T-ALL52.
In addition to TAD boundary changes, we also found prevalent 
intra-TAD activity differences between T-ALL and T cells, as well 
as between the two subtypes of T-ALL. The changes in intra-TAD 
activity correlated with expression changes, super-enhancer activ-
ity, NOTCH1 binding and insulation mediated by CTCF binding at 
these TAD boundaries, which appeared to be independent of com-
partment shifts. Supporting a prominent role for intra-TAD activ-
ity changes in modulating gene expression, recent studies tracking 
3D chromatin modifications during developmental processes such 
as embryonic stem cell differentiation and neural development 
identified significant changes in interactions within (sub-)TADs 
that correlated with transcriptional levels and epigenetic states53,54. 
Furthermore, in line with our findings, negative correlations of 
Fig. 6 | CDK7 inhibition concomitantly reduces H3K27ac levels and associated enhancer–promoter looping. a, LOLA analysis of public ChIP–seq data 
for CUTLL1 and Jurkat cells in the LOLA database for γSI-insensitive and γSI-sensitive enhancers. Statistical differences in overlap of γSI-insensitive and 
γSI-sensitive enhancers with ChIP–seq peaks were calculated by two-sided Fisher’s exact test. b, H3K27ac occupancy in CUTLL1 cells. Groups consisted 
of stable (middle, white; n = 1,396), increased (top, gray; n = 2,246) and reduced (bottom, purple; n = 3,248) non-promoter H3K27ac signal. The heat 
map shows the H3K27ac signal as fold enrichment over input, and line plots depict quantification of H3K27ac signal. Differential analysis was performed 
with the R package DiffBind using the edgeR method, and differential peaks were selected by FDR < 0.05 and log2 (fold change) >1.0 or <−1.0. Number 
of replicates: CUTLL1 DMSO, n = 4; CUTLL1 ΤΗΖ1, n = 2. c, Changes in Hi-C interactions between the non-promoter H3K27ac peaks defined in b and 
connected gene promoters (defined by CUTLL1 H3K27ac HiChIP), shown as the log2 (fold change) (average of n = 2 replicates). Each dot represents 
an enhancer–promoter interaction. The significance of shifts in comparison to enhancer–promoter interactions associated with stable enhancers was 
calculated by unpaired one-sided t test. d,e, 4C–seq using the MYC (d) and IKZF2 (e) promoter as the viewpoint. The positive y axis shows interactions 
with the viewpoint as normalized read counts, and the negative y axis shows the significance of differential interactions as log10 (P value) calculated with 
the edgeR function glmQLFTest. Tracks below show H3K27ac and CDK7 ChIP–seq tracks and represent fold enrichment over input where applicable 
and counts per million reads otherwise. The gray areas indicate MYC super-enhancer elements (d) or IKZF2 enhancer (e). Number of replicates: CUTLL1 
DMSO 4C MYC, n = 3; CUTLL1 THZ1 4C MYC, n = 3; CUTLL1 DMSO 4C IKZF2, n = 3; CUTLL1 THZ1 4C IKZF2, n = 3; CUTLL1 DMSO H3K27ac, n = 2; CUTLL1 
THZ1 H3K27ac, n = 2; Jurkat CDK7, n = 1. Box-plot information can be found in the Source Data.
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intra-TAD interactions with repressive histone marks have been 
reported in EZH2-mutant lymphomas55. Herein our observations 
suggest that gene expression changes in cancer cells are frequently 
associated with correlative changes in intra-TAD activity, CTCF 
insulation and enhancer activity. On a cautionary note, precise 
identification of 3D chromatin architectural changes in cancer cells 
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depends on comparison with the respective cell-of-origin popula-
tion. Although the cell of origin of each of our T-ALL samples is 
unknown, pilot experiments comparing the 3D chromatin archi-
tecture of T-ALL cells to that of human thymic (CD4+CD8+) pro-
genitors from healthy donors identified similar intra-TAD activity 
differences specific to T-ALL (data not shown). Further studies are 
required to understand a possible correlation between the cell of 
origin and leukemia and to even address potential 3D landscape dif-
ferences between individual leukemia samples.
Finally, we also addressed the role of oncogenic NOTCH1 in 
organizing the 3D chromosomal landscape associated with T-ALL 
transformation and to what extent changes can be reversed by 
inhibiting NOTCH signaling. NOTCH signaling inhibition is a 
powerful means to inhibit growth of NOTCH1-induced T-ALL41,56. 
The effects of γSI have been reported to be selective to dynamic 
NOTCH1 sites, which are predominantly located within enhanc-
ers21,38. Dynamic NOTCH1 sites are also associated with a decrease 
in enhancer activity after γSI treatment. These findings prompted 
us to further investigate the impact of NOTCH1 inhibition on 
remodeling of the 3D landscape in leukemia. Our studies showed 
that NOTCH1 inhibition using γSI had no effect on global 3D chro-
matin structure but targeted enhancer–promoter interactions in 
selected NOTCH1-regulated loci. More specifically, we identified 
enhancer–promoter loops of dynamic NOTCH1-bound enhancers 
also associated with a decrease in H3K27ac after γSI treatment that 
were particularly sensitive to NOTCH1 inhibition. These results 
concur with a recent report that demonstrated a role for NOTCH1 
in facilitating specific long-range interactions in triple-negative 
breast cancer and mantle cell lymphoma18.
In an attempt to further understand the importance of NOTCH1 
binding in maintaining certain enhancer–promoter loops but not 
others, we initially found that the enhancers most sensitive to 
NOTCH1 inhibition tended to be shorter in length. The longer 
stretch of ‘insensitive’ enhancers might enable other factors to bind 
and/or keep the chromatin in an open and accessible state for long-
range chromatin interactions57, thus offering a potential explana-
tion for the variance in enhancer–promoter looping changes we 
observed for NOTCH1 targets, including MYC, IKZF2, APCDD1 
and LUNAR1. In agreement with this hypothesis, we found enrich-
ment for CDK7 binding in γSI-insensitive enhancers relative to γSI-
sensitive enhancers. CDK7 is a kinase previously shown to control 
the function of RNA polymerase II-mediated transcription58. CDK7 
inhibition has been shown to have significant effects in hematologi-
cal malignancies and other cancer types47,59,60. We here showed that 
pharmacological inhibition of CDK7 in T-ALL by THZ1 resulted 
in a widespread decrease in enhancer activity as quantified by 
H3K27ac levels. Enhancers with strong reduction of H3K27ac were 
also associated with a significant decrease in enhancer–promoter 
contacts, including the γSI-insensitive loci for MYC and IKZF2. 
This clearly highlights the complexity of super-enhancer activity 
and the factors that dictate super-enhancer interactions with gene 
promoters. Overall, our study underscores the need for further 
investigation of factors that maintain or rewire 3D chromosomal 
interactions, especially during cellular transformation, as they could 
be potential targets for small-molecule drug development.
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Methods
Cell culture. The CUTLL1 human cell line and Jurkat cells were cultured in 
RPMI-1640 medium supplemented with 10% FBS, penicillin, streptomycin 
and glutamine. Naive CD4+ T cells were purchased from Lonza and cultured in 
X-vivo 15 culture medium (Lonza) supplemented with 5% human serum (Gemini 
Bioproducts) and 10 ng ml–1 human interleukin (IL)-2.
Primary T-ALL samples. Primary samples from individuals with T-ALL were 
collected by Columbia Presbyterian Hospital or Weill Cornell Medical College  
with informed consent and approved and analyzed under the supervision of  
the Columbia University Medical Center Institutional Review Board or the Weill 
Cornell Medical College Institutional Review Board. For expansion of these cells, 
1 × 106 cells were transplanted into immunodeficient NOD-SCID-gamma (NSG) 
mouse strains via retro-orbital injection, as previously performed63.  
Cells collected from the spleen of these primary recipients were used for the  
in situ Hi-C experiment. All mouse experiments were performed according to 
ethical guidelines set by the Institutional Animal Care and Use Committee and 
New York University.
In situ Hi-C. In situ Hi-C was performed as described in Rao et al.64. Primary 
samples were processed as one replicate, and all cell line experiments were 
processed with two biological replicates. Briefly, 20 million cells were fixed in 
1% formaldehyde for 10 min. Fixed cells were permeabilized in 1 ml lysis buffer 
(10 mM Tris-HCl pH 8, 10 mM NaCl, 0.2% NP-40 and protease inhibitor cocktail 
(Sigma)) for 15 min on ice and spun down (2,000g, 5 min, 4 °C). Cell pellets were 
resuspended in 345 μl of 1× NEBuffer2 (NEB) per aliquot of 5 million cells, and 
38 μl of 1% SDS was added to each aliquot, followed by incubation at 65 °C for 
10 min. Then, 43 μl of 10% Triton X-100 was added to quench the SDS. To digest 
chromatin, 400 U of HindIII (NEB) was added per aliquot and samples were 
incubated at 37 °C overnight with continuous agitation (900 r.p.m.). After digestion, 
restriction sites were filled in with Klenow (NEB) in the presence of biotin-14–dATP 
(Life Technologies), dCTP, dGTP and dTTP for 2 h at 37 °C. Blunt-end ligation 
was performed by adding 700 µl of ligation mix (containing 50 U of T4 DNA ligase 
(Invitrogen)), followed by overnight incubation at 16 °C.
Cross-links were reversed by adding 50 μl of 10 mg ml–1 proteinase K 
(Invitrogen) per aliquot and incubating at 65 °C for 2 h, followed by addition of 
another 50 μl of 10 mg ml–1 proteinase K and incubation overnight. All aliquots 
for each replicate were pooled, and DNA was extracted by phenol-chloroform 
extraction protocol. RNA was digested by adding 1 μl of 1 mg ml–1 RNase A (Sigma) 
and incubating at 37 °C for 30 min. Biotin was removed from nonligated restriction 
fragment ends by incubating 40 μg of DNA with T4 DNA polymerase (NEB) for 
4 h at 20 °C in the presence of dATP and dGTP. After purification (Amicon Ultra 
30K) and sonication (Covaris E220), the DNA was double size selected on AMPure 
XP beads (Beckman Coulter, 0.8−1.1×). End repair was performed with T4 DNA 
polymerase (NEB), T4 DNA polynucleotide kinase (NEB), Klenow (NEB) and 
dNTPs in 1× T4 DNA ligase reaction buffer (NEB), followed by dATP addition with 
Klenow. Biotin-marked ligation products were isolated with MyOne Streptavidin 
C1 Dynabeads (Life Technologies). Paired-end adaptors (Illumina) were ligated 
to DNA fragments by using 15 U of T4 DNA ligase (Invitrogen) for 2 h at room 
temperature. Bead-bound DNA was amplified with six PCR amplification cycles 
using PE PCR 1.0 and PE PCR 2.0 primers (Illumina). Primary T-ALL samples 2–5, 
the sample from T cell donor 2 and the ETP-ALL samples along with the CUTLL1 
samples treated with DMSO or THZ1 were processed with the commercial Arima 
Genomics HiC kit according to the manufacturer’s guidelines. The Hi-C libraries 
were sequenced on the Illumina HiSeq 2500 or 4000 platform at 50 cycles.
4C–seq. For the LUNAR1 and APCDD1 viewpoints, we created biological 
duplicates for all experiments. For the MYC viewpoint, we created five biological 
replicates for CUTLL1 cells treated with DMSO, three replicates for CUTLL1 cells 
treated with γSI and two replicates for T cells. Experiments with edited T cells were 
performed with two replicates, and CUTLL1 cells were treated with DMSO or 
THZ1 in biological triplicate.
For each replicate, 10 million cells were fixed in 2% formaldehyde and 10%  
FBS in PBS for 10 min at room temperature. For edited and wild-type T cells,  
5 million cells were used. Cross-linking was quenched with glycine, and 4C–seq 
was performed as described previously16. Cells were lysed on ice with 1 ml lysis 
buffer (50 mM Tris pH 7.3, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40 and 1% Triton 
X-100) for 15 min. Nuclei were spun down and resuspended in 360 μl water (or 
frozen). Then, 60 μl of 10× DpnII restriction buffer was added along with 15 μl of 
10% SDS, and samples were left shaking for 1 h at 37 °C, followed by addition of 
150 μl of 10% Triton X-100 and additional shaking for 1 h at 37 °C. Five microliters 
of undigested control was stored, and nuclei were incubated overnight with 200 U 
of DpnII restriction enzyme (NEB, R0543M). A fresh 200 U of DpnII was added 
the following morning, and samples were digested for 6 h. After this, digestion was 
checked for completion by running 5 μl of sample in a 1% agarose gel. DpnII was 
inactivated with 80 μl of 10% SDS, and a proximity ligation reaction was performed 
in a 7-ml volume with 4,000 U of T4 DNA ligase (NEB, M0202M). Cross-links 
were reversed at 65 °C overnight after adding 300 μg proteinase K. Samples were 
then treated with 300 μg RNase A for 45 min at 37 °C, and DNA was ethanol 
precipitated. A second restriction digest was performed overnight in a 500-μl 
reaction with 50 U of Csp6l (Fermentas, ER0211). The enzyme was inactivated 
at 65 °C for 25 min, and a proximity ligation reaction was performed in a 14-ml 
volume with 6,000 U of T4 DNA ligase. Sample DNA was ethanol precipitated 
and purified with the QIAquick PCR purification kit (Qiagen). To generate the 
4C–seq library, 1 μg of prepared 4C template was amplified with 30 PCR cycles per 
bait for each condition (see Supplementary Table 6 for viewpoint sequences), and 
the amplified fragments were sequenced on the Illumina HiSeq 2500 platform to 
generate single-end reads at 50 cycles.
HiChIP. HiChIP was performed as previously described42 with some 
modifications. In brief, up to 10 million cross-linked cells were resuspended in 
500 μl of ice-cold HiC lysis buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 0.2% 
NP-40 and 1× protease inhibitors) and rotated at 4 °C for 30 min. Nuclei were 
pelleted and washed once with 500 μl of ice-cold HiC lysis buffer. The pellet was 
then resuspended in 100 μl of 0.5% SDS and incubated at 62 °C for 10 min. Then, 
285 μl of water and 50 μl of 10% Triton X-100 were added, and samples were 
rotated at 37 °C for 15 min. To this, 50 μl of NEBuffer 2 and 15 μl of 25 U μl–1 MboI 
restriction enzyme (NEB, R0147) were added, and samples were rotated at 37 °C 
for 2 h. MboI was heat inactivated at 62 °C for 20 min. Then, 52 μl of incorporation 
master mix (37.5 μl of 0.4 mM biotin–dATP (Jena Biosciences, NU-835-BIO14-S), 
1.5 μl of a dCTP, dGTP and dTTP mix (10 mM each) and 10 μl of 5 U μl–1 Klenow 
fragment (NEB, M0210)) was added. Reactions were rotated at 37 °C for 1 h, and 
948 μl of ligation master mix (150 μl of 10× NEB T4 DNA ligase buffer with 10 mM 
ATP (NEB, B0202), 125 μl of 10% Triton X-100, 3 μl of 50 mg ml–1 BSA (Thermo 
Fisher, AM2616), 10 μl of 400 U μl–1 T4 DNA ligase (NEB, M0202) and 660 μl 
of water) was added. Reactions were rotated at room temperature for 4 h. After 
proximity ligation, nuclei were pelleted and the supernatant was removed. The 
nuclear pellet was resuspended in 880 μl of nuclear lysis buffer (50 mM Tris-HCl 
pH 7.5, 10 mM EDTA, 0.5% SDS and 1× Roche protease inhibitor (11697498001)) 
and sonicated with a Bioruptor 300 (Diagenode) for eight cycles of 30 s each, on the 
high setting. Clarified samples were transferred to Eppendorf tubes and diluted 1:5 
with ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
Tris-HCl pH 7.5 and 167 mM NaCl). Cells were precleared with 30 μl of Protein G 
Dynabeads (Life Technologies, 10004D) by rotation at 4 °C for 1 h. Supernatants 
were transferred to fresh tubes, and antibody was added (7.5 µg of anti-H3K27ac 
antibody for 10 million cells). Samples were incubated overnight at 4 °C. The next 
day, 30 μl of Protein G Dynabeads was added and samples were rotated at 4 °C 
for 2 h. After bead capture, beads were washed with low-salt wash buffer (0.1% 
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 7.5 and 150 mM NaCl), 
high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl 
pH 7.5 and 500 mM NaCl) and LiCl wash buffer (10 mM Tris-HCl pH 7.5, 250 mM 
LiCl, 1% NP-40, 1% sodium deoxycholate and 1 mM EDTA). Samples were eluted 
with 150 μl of DNA elution buffer (50 mM sodium bicarbonate pH 8.0 and 1% 
SDS, freshly made) and incubated at 37 °C for 30 min with rotation. Supernatant 
was transferred to a fresh tube, and elution was repeated with another 150 μl of 
elution buffer. Then, 5 μl of proteinase K (20 mg ml–1; Thermo Fisher) was added 
to the 300-μl reaction, and samples were incubated overnight at 65 °C. Samples 
were purified with DNA Clean and Concentrator columns (Zymo Research) and 
eluted in 10 μl of water. Post-ChIP DNA was quantified by Qubit (Thermo Fisher), 
and 5 μl of Streptavidin C1 beads (Thermo Fisher) was washed with Tween wash 
buffer (5 mM Tris-HCl pH 7.5, 0.5 mM EDTA, 1 M NaCl and 0.05% Tween-20) and 
then resuspended in 10 μl of 2× biotin binding buffer (10 mM Tris-HCl pH 7.5, 
1 mM EDTA and 2 M NaCl). Beads were added to the samples, which were then 
incubated at room temperature for 15 min with shaking. After capture, beads were 
washed twice by adding 150 μl of Tween wash buffer and incubating at 55 °C for 
2 min with shaking. Samples were then washed in 100 μl of 1× TD buffer (2× TD 
buffer: 20 mM Tris-HCl pH 7.5, 10 mM MgCl2 and 20% dimethylformamide). After 
washes, beads were resuspended in 22 μl of Arima elution buffer, and the library 
was generated on Streptavidin C1 beads with a modified Kapa Library Preparation 
kit. End repair and adaptor ligation were carried out on 20 μl of bead-bound DNA. 
Then, 1 μl of 15 μM Illumina TruSeq sequencing adaptors was added to the sample 
along with 49 μl of master mix containing DNA ligase, ligase buffer and PCR-grade 
water, and samples were incubated at 20 °C for 15 min. After adaptor ligation, the 
samples were washed twice with Arima wash buffer and incubated at 55 °C for 
2 min with shaking. The samples were washed once more with 100 μl of elution 
buffer and finally resuspended in 22 μl of elution buffer. To each sample, 25 μl of 
HiFi HotStart Ready Mix and 10× primer mix (Kapa Library Amplification Kit) 
were added. The following PCR program was performed: 98 °C for 45 s followed by 
ten cycles at 98 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s, with a final extension 
completed at 72 °C for 1 min (cycle number was estimated on the basis of the 
amount of material from the post-ChIP Qubit reading (approximately 50 ng was 
run in six cycles, while 25 ng was run in seven cycles, 12.5 ng in eight cycles, etc.). 
Libraries were sequenced on the Illumina HiSeq 4000 platform on PE50 mode.
In vitro drug treatment. CUTLL1 cells were treated with γSI (Compound E) 
purchased from Alexis Bioscience at a 1 μM final concentration. Treatment  
was performed every 12 h for 72 h. THZ1 was purchased from Cayman  
Chemical (9002215), and cells were treated at a 100 nM final concentration every 
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12 h for 24 h. For 5-azacytidine, cells were treated with a 100 nM concentration 
every day for 3 d (72 h).
GRO-seq and library preparation. GRO-seq was performed in CUTLL1 cells 
treated with either DMSO or γSI at a 1 μM concentration for 72 h. All experiments 
were performed in biological duplicate. GRO-seq sample preparation was 
performed as described previously65. Briefly, nuclei were isolated in swelling buffer 
(10 mM Tris-HCl pH 7.5, 2 mM MgCl2 and 3 mM CaCl2), lysed twice in lysis buffer 
(10 mM Tris-HCl pH 7.5, 2 mM MgCl2, 3 mM CaCl2, 10% glycerol and 0.5% NP-40) 
and snap frozen in freezing buffer (50 mM Tris pH 8.0, 40% glycerol, 5 mM MgCl2 
and 0.1 mM EDTA), For the run-on reaction, an equal volume of reaction buffer 
was added to thawed nuclei (10 mM Tris pH 8.0, 5 mM MgCl2, 300 mM KCl, 500 μM 
ATP, 500 μM GTP, 5 μM CTP, 500 μM BrUTP, 1 mM dithiothreitol, 100 U ml–1 
SuperaseIN and 1% sarkosyl), and samples were mixed and incubated at 30 °C for 
5 min. The reaction was stopped with TRIzol reagent, and RNA was extracted with 
phenol-chloroform and ethanol precipitated. RNA was heated in fragmentation 
buffer (40 mM Tris pH 8.0, 100 mM KCl, 6.25 mM MgCl2 and 1 mM dithiothreitol), 
treated with DNase and purified with Zymo RNA Clean and Concentrator 
columns (Zymo Research) by using the >17-nucleotide protocol. Run-on RNA was 
immunoprecipitated with BSA-blocked BrDU beads (Santa Cruz Biotechnology) 
in binding buffer (0.5× SSPE, 1 mM EDTA and 0.05% Tween-20) for 1 h at 4 °C, 
washed and eluted in elution buffer (5 mM Tris pH 7.5, 300 mM NaCl, 20 mM 
dithiothreitol, 1 mM EDTA and 1% SDS) at 65 °C for 20 min. Nascent RNA was 
further extracted with phenol-chloroform, and sequencing libraries were prepared.
Sanger sequencing of the CTCF-binding site in the MYC locus. Genomic DNA 
from CUTLL1, Jurkat and T-ALL 1 cells was isolated with the Qiagen DNeasy kit 
according to the manufacturer’s guidelines. The target locus was PCR amplified 
with Phusion High-Fidelity PCR Master Mix (Thermo Fisher, F531S) using 100 ng 
of genomic DNA as the template. Primer sequences are listed in Supplementary 
Table 6. PCR products were purified on Qiagen PCR purification columns and 
submitted for Sanger sequencing to Genewiz.
CTCF-motif-targeting guide RNA sequence. The guide RNA target sequence 
was 5′-UCUACAACAUCUCCACCAUG-3′. The guide RNA along with the tracer 
RNA was purchased as a synthetic guide RNA from Synthego with 2′-O-methyl 
and 3′-phosphorothioate modifications of the first and last three nucleotides.
Editing of T cells. Naive T cells were activated with CD3/CD28 beads from 
Thermo Fisher Scientific (11161D) for 48 h. After activation, the CD3/CD28 beads 
were magnetically removed and 2 million activated T cells were transfected by 
electrotransfer with either ribonucleoprotein complex consisting of 1.5 µg of Cas9 
protein and 1 µg of guide RNA or 1.5 µg of Cas9 protein alone for every 200,000 
cells using the Neon transfection system at 1,200 V with a width of 40 and one pulse. 
After electroporation, cells were diluted into culture medium at 106 cells per ml.  
The electroporation step was repeated after 24 h. Forty-eight hours after the 
second transfection, genomic DNA was isolated. The target CTCF region was PCR 
amplified and subjected to Sanger sequencing. Editing efficiency was computed by 
using the ICE computational program from Synthego.
High-throughput 3D DNA FISH. Generation of FISH probes. Custom FISH probes 
targeting the MYC promoter and enhancer were designed with the SureDesign 
custom oligonucleotide design tool from Agilent with homology to the regions of 
interest mined from the hg19 genome build, using the default parameters of the 
SureDesign tool. The MYC promoter probe library targeted a 60-kb region centered 
on the promoter, whereas the enhancer probe library targeted a 100-kb region 
including the center enhancer element of the MYC super-enhancer cluster.
3D FISH experimental protocol. 3D FISH was performed with the Dako FISH 
Histology accessory kit from Agilent (K579911-5) according to the manufacturer’s 
guidelines. Briefly, 200,000 cells were cytospun to poly(l-lysine)-treated 
glass slides at 1,200 r.p.m. for 5 min. Cells were subsequently fixed for 10 min 
with 4% formaldehyde in PBS at room temperature, followed by membrane 
permeabilization with 0.5% Triton X-100 in PBS for 20 min at room temperature. 
Slides were washed once in 1× PBS followed by RNase treatment (100 µg ml–1 
RNase A in 2× SSC buffer). Cells were then washed with 2× SSC and dehydrated 
through an alcohol series (2 × 100% ethanol and 2 × 70% ethanol, 2 min each at 
room temperature). Slides were washed with 1× Dako wash buffer for 5 min at 
room temperature and then treated with 1× Dako pretreatment solution at 98 °C 
for 2 min and allowed to cool for 15 min at room temperature. After pretreatment, 
slides were washed twice with 1× Dako wash buffer for 3 min each at room 
temperature. Slides were then treated with cold pepsin at 37 °C for 2 min followed 
by two washes with 1× Dako wash buffer for 3 min each at room temperature. 
Slides were then dehydrated through a series of ethanol washes (70%, 80% and 
100% ethanol, 2 min each at room temperature). After the ethanol washes, slides 
were air dried and set up for probe hybridization. For each slide, 1 µl of each probe 
mixed with 9 µl of IQFISH Fast Hybridization buffer was added, and slides were 
covered with a coverslip and sealed with rubber cement. Slides were incubated 
at 80 °C in a heat block for 10 min followed by incubation for 90 min in a hot-air 
oven set at 45 °C in the dark. After hybridization, the rubber cement was removed 
and the slides were washed with 1× Dako stringent wash buffer for 5 min at room 
temperature. This was immediately followed by a second wash with 1× Dako 
stringent wash buffer for 10 min at 56 °C. The stringent washes were followed by 
two washes with 1× Dako wash buffer for 3 min each at room temperature. Slides 
were then dehydrated through a series of ethanol washes (70%, 80% and 100% 
ethanol, 2 min each at room temperature), air dried and mounted with coverslips 
using Immune-mount with DAPI stain.
Computational analysis. Raw sequencing data were mostly processed with the 
hic-bench platform29. Detailed descriptions of individual analyses can be found in 
the Supplementary Methods.
Further detailed information on experimental design and reagents can be 
found in the Nature Research Reporting Summary.
Statistics and reproducibility. All sequencing experiments and functional analyses 
involved at least two replicates that were independently prepared, cultured and 
treated, including experiments with cell lines (CUTLL1, Jurkat and activated 
T cells) or xenografts of different primary samples from patients, obtained by using 
independent recipient mice for each replicate.
Statistical analyses for differential gene expression, differential ChIP–seq peaks 
and differential 4C–seq peaks were conducted with the R Bioconductor package 
edgeR using two or more independent replicates as described above (after intra-
sample sequencing depth normalization with the ‘cpm’ function and inter-sample 
dispersion correction with the ‘estimateCommonDisp’ and ‘estimateTagwiseDisp’ 
functions, followed by ‘glmQLFit’ and ‘glmQLFTest’ for differential analysis). 
Differential Hi-C analysis, based on either compartment scores or TAD activity 
scores, was performed with two-sided t tests.
The statistical significance of differences in odds ratios between two groups 
(Figs. 2f, 5b and 6a) was calculated by two-sided Fisher’s exact test.
When we expected changes in one direction, we used one-tailed t tests under 
the following hypotheses (Fig. 2d,e,g):
H0: The mean expression of genes associated with differential intra-TAD 
activity (for example, expression fold change T-ALL/T-cells in T-ALL-specific 
TADs) or the mean CTCF binding strength of peaks associated with differential 
intra-TAD activity is unchanged or has a negative correlation with intra-TAD 
activity changes.
Example : μT-ALL-specific TADs ≤ μconstant TADs
IHA: The mean expression of genes associated with differential intra-TAD 
activity (for example, expression fold change T-ALL/T-cells in T-ALL-specific 
TADs) or the mean CTCF binding strength of peaks associated with differential 
intra-TAD activity has a positive correlation with intra-TAD activity changes.
Example : μT-ALL-specific TADs>μconstant TADs
ISimilarly, for comparisons of enhancer–promoter loops or associated 
expression of genes connected with enhancers of reduced activity (Figs. 5c,d and 6c), 
we used one-tailed t tests under the following hypotheses:
H0: The mean looping strength of enhancer–promoter pairs in treated CUTLL1 
cells is greater than or equal to the looping strength of enhancer–promoter pairs 
in untreated CUTLL1 cells or the mean expression of associated genes in treated 
CUTLL1 cells is greater than or equal to the expression of associated genes in 
untreated CUTLL1 cells.
Example : μtreatedCUTLL1≥μuntreated CUTLL1
IHA: The mean looping strength of enhancer–promoter pairs in treated CUTLL1 
cells is less than the looping strength of enhancer–promoter pairs in untreated 
CUTLL1 cells or the mean expression of associated genes in treated CUTLL1 cells 
is less than the expression of associated genes in untreated CUTLL1 cells.
Example : μtreatedCUTLL1<μuntreatedCUTLL1
ILastly, for comparisons of 3D FISH probe distances used for validation of 
genome-wide comparisons (Fig. 4e and Extended Data Fig. 10d), we used  
one-tailed Kolmogorov–Smirnov tests under the following hypotheses:
H0: The mean distance between the probes in T-ALL is greater than or equal to 
the distance between the probes in T-cells or the mean distance between the probes 
in treated T-ALL is greater than or equal to the distance between the probes in 
untreated T-ALL.
Example : μT-ALL≥μT cells
IHA: The mean distance between the probes in T-ALL is smaller than the 
distance between the probes in T cells or the mean distance between the probes in 
treated T-ALL is smaller than the distance between the probes in untreated T-ALL.
Example : μT-ALL<μT cells
IThe number (n) of independent replicates tested and the statistical test used in 
each case are described in the respective figure legends; exact P values are indicated 
in the respective figure in all cases.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All sequencing data created in this study have been uploaded to the Gene 
Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) and are available 
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under accession code GSE115896. Biological material used in this study can be 
obtained from the authors upon request. Source data for Figs. 2–6 and Extended 
Data Figs. 1–3, 5, 7, 9 and 10 are provided with the paper.
Code availability
All code for Hi-C analysis is available within the previously published Hi-C bench 
platform (https://github.com/NYU-BFX).
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Extended Data Fig. 1 | See next page for caption.
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Extended Data Fig. 1 | Hi-C quality control and unsupervised analyses. a) Read alignment statistics for Hi-C datasets, as absolute reads (left) and relative 
reads (in %, right). “ds.accepted.intra” are all intra-chromosomal reads used for all downstream analyses. b) Genome-wide stratum-adjusted correlation 
coefficient (SCC) scores for all pair-wise comparisons of the Hi-C datasets. HiCRep was used to calculate chromosome-wide correlation scores, which 
were averaged across all chromosomes for each pair-wise comparison. The HiCRep smoothing parameter X was set to 1.0. c) Principal Component 
Analysis (PCA) of the genome-wide compartment scores for each Hi-C dataset. Number samples: T cells n = 3; T-ALL n = 6, ETP-ALL n = 4. d)  
Compartment shifts between T cells, T-ALL and ETP-ALL. Assignment of A compartment was done using an average c-score > 0.1 in either all T cell, 
T-ALL or ETP-ALL samples and B compartment with average c-score < -0.1. Significance for differences between pairwise comparisons of T cells, T-ALL 
and ETP-ALL was determined using a two-sided t test between c-scores, and compartment shifts were determined using P value < 0.1. e) Integration of 
gene expression associated with compartment shifts for comparisons of T cell vs T-ALL (left) or T-ALL vs ETP-ALL (right) using RNA-seq (FPKM > 1). 
For each gene within the respective compartment bin, log2 fold-change between T cells and T-ALL (left) or between T-ALL and ETP-ALL (right) is shown. 
Significant differences are calculated using an unpaired one-sided t test comparing genes from A to A compartments (that is active compartment) with 
genes from A to B or B to A compartment shifts, following the hypothesis of a positive correlation between expression and compartment association. 
Boxplot information can be found as additional Source Data.
NATurE GENETICS | www.nature.com/naturegenetics
Articles Nature GeNetics
Extended Data Fig. 2 | See next page for caption.
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Extended Data Fig. 2 | Genomic loci displaying differential intra-TAD activity in T-ALL. a) Hi-C interaction heat maps (first row) showing the IKZF2 locus 
(black circle). Second row shows heat maps of log2 (fold-change) interactions compared to T cell 1. b) H3K27ac ChIP-seq tracks for IKZF2 locus in  
T cells and CUTLL1, NOTCH1 ChIP-seq tracks for CUTLL1. Tracks represent fold-enrichment over input where applicable and counts-per-million reads 
otherwise. Grey area indicates TAD containing IKZF2. Number replicates: T cells H3K27ac n = 2; CUTLL1 H3K27ac n = 2; CUTLL1 NOTCH1 n = 1. c) 
Quantifications for intra-TAD activity (left; as highlighted in a) and expression of IKZF2 (right). Statistical evaluation for intra-TAD activity was performed 
using paired two-sided t test of average per interaction-bin for IKZF2 TAD between T cells (n = 3) and T-ALL (n = 6), followed by multiple testing 
correction. Log2 FPKM of IKZF2 expression for T cells (n = 13) and T-ALL (n = 6) samples; statistical evaluation was performed using edgeR followed by 
multiple testing correction. d) Hi-C interaction heat maps (first row) showing the CYLD locus (black circle). Second row shows heat maps of log2 (fold-
change) interactions when compared to T-cell 1. e) H3K27ac ChIP-seq tracks for CYLD locus in T cells and CUTLL1, NOTCH1 ChIP-seq tracks for CUTLL1. 
Tracks represent fold-enrichment over input where applicable and counts-per-million reads otherwise. Grey area indicates TAD containing CYLD. Number 
replicates: T cells H3K27ac n = 2; CUTLL1 H3K27ac n = 2; CUTLL1 NOTCH1 n = 1. f) Quantifications for intra-TAD activity (left; as highlighted in D)) and 
expression of CYLD (right). Statistical evaluation for intra-TAD activity was performed using paired two-sided t test of average per interaction-bin for 
CYLD TAD between T cells (n = 3) and T-ALL (n = 6), followed by multiple testing correction (see methods). Log2 FPKM of CYLD expression for T cells 
(n = 13) and T-ALL (n = 6); statistical evaluation was performed using edgeR followed by multiple testing correction. Boxplot information can be found as 
additional Source Data.
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Extended Data Fig. 3 | Intra-TAD activity cross-comparison of T-ALL sub-types. a) Comparisons of intra-TAD activity between T cells, T-ALL and ETP-
ALL samples. b) Overlap of differentially active TADs between the two comparisons of T cells vs T-ALL and T cells vs ETP-ALL, visualized as venn diagram. 
Red and blue colors correspond to differences as highlighted in a). c, d) Integration of RNA-seq (FPKM > 1) within TADs with decreased / increased intra-
TAD activity for ETP-ALL vs T cells (c) and ETP-ALL vs T-ALL (d). For each such gene, the log2 (fold-change) in expression between ETP-ALL and T cells 
(c) / T-ALL and ETP-ALL (d) taken from RNA-seq is shown. Significant differences are calculated by an unpaired one-sided t test comparing genes from 
TADs with decreased / increased intra-TAD activity with genes from stable TADs, following the hypothesis of a positive correlation between expression 
and intra-TAD activity changes. Boxplot information can be found as additional Source Data.
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Extended Data Fig. 4 | WGS integration with TAD boundaries altered in T-ALL. a, b) Overlap of altered TAD boundaries as in Fig. 3c, d with genomic 
inversions (a) or insertions/deletions (indels) (b) from WGS of T-ALL 1 (top) and T-ALL 2 (bottom). Overlap was determined by bedtools intersect, using 
a 1 bp overlap for indels and 100 kb for individual inversion breakpoints (instead of the entire genomic range affected by the inversion). c) Overlap of 
individual translocation breakpoints (calculated from T-ALL Hi-C samples as in Supplementary Fig. 1B) with TAD boundaries displaying changes in TAD 
insulation between T cells and T-ALL. Overlap was determined by bedtools intersect, using a 1 bp overlap.
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Extended Data Fig. 5 | Difference in CTCF insulation in MYC locus is not due to genomic mutation but potentially regulated by open chromatin.  
a) CTCF ChIP-qPCR of the CTCF binding site in the lost MYC TAD boundary, shown as fold-enrichment over input. Significant differences compared to 
T cells were calculated with an unpaired one-sided t test, following the hypothesis of loss of CTCF binding in T-ALL samples as determined from the 
genome-wide analysis (n = 3 replicates for T cells, T-ALL 1, T-ALL 2, CUTLL1 and Jurkat; n = 2 replicates for T-ALL 3 and T-ALL 4). Error bars indicate s.d.; 
center value indicates mean. b) Targeted sanger sequencing indicates no mutation in T-ALL in the CTCF binding site at the MYC TAD boundary. Tracks 
show chromatogram of individual base calls (left). Whole genome sequencing indicates no mutation in T-ALL in the motif of CTCF binding site. Tracks 
show (mis-)matches compared to reference sequence in all reads covering the respective genomic position (right). c) CTCF ChIP-qPCR before and after 
treatment with global DNA-demethylation agent 5-azacytidine (n = 2 replicates). d) ATAC-seq quantification for T cells and Jurkat for the genomic 
area covering loss of CTCF binding in the downstream TAD boundary of MYC. Data was normalized to the average T cell signal, shown in percent (n = 3 
replicates). Statistical evaluation was performed using DiffBind with edgeR-method, following multiple testing correction. Error bars indicate s.d.; center 
value indicates mean.
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Extended Data Fig. 6 | 4C-Seq validation of MYC super-enhancer interaction in primary T-ALL. a) 4C-seq analysis using MYC promoter as viewpoint. 
Positive y-axis shows interactions with the MYC promoter viewpoint as normalized read counts, negative y-axis shows significance of differential 
interactions between T cells and primary T-ALL samples as log10(P value) derived using edgeR function glmQLFTest. H3K27ac ChIP-seq tracks for T cells 
and CUTLL1 are represented below as fold-enrichment over input. Grey areas indicate MYC super-enhancer elements. Number replicates: T cells 4 C n = 2; 
T-ALL 1 4 C n = 1; T-ALL 2 4 C n = 2; T cells H3K27ac n = 2; CUTLL1 H3K27ac n = 2.
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Extended Data Fig. 7 | CrISPr-Cas9 deletion of CTCF binding site shows loss of insulation around MYC locus. a) Schematic of Cas9+Synthetic guide 
transfection of activated T cells. b) Sequence showing CTCF motif in the insulator region in T cells targeted for CRISPR-based deletion. sgRNA targeting 
sequence within the CTCF motif is highlighted. Sequencing of sgRNA target site indicates various indels along with frequencies observed for each indel.  
c) CTCF ChIP-qPCR validation of reduced CTCF binding in edited T cells compared to unedited T cells (n = 2 replicates). d) qPCR comparing MYC 
expression in edited T cells compared to unedited T cells (n = 3 replicates). Statistical significance was determined using unpaired two-sided t test. Error 
bars indicate s.d.; center value indicates mean. e) 4C-seq analysis using MYC promoter as viewpoint in edited and unedited T cells. Positive y-axis shows 
interactions with the viewpoint as normalized read counts, negative y-axis shows significance of differential interactions between the two samples as 
log10(P value) calculated with edgeR function glmQLFTest. Tracks below show CTCF ChIP-seq in CUTLL1 and H3K27ac ChIP-seq in naïve T cells and 
CUTLL1 as fold-enrichment over input. Grey area indicates deleted CTCF binding site. Number replicates: T cells WT 4 C n = 2; T cells Edited 4 C n = 2; 
T cells CTCF n = 2; T cells H3K27ac n = 2; CUTLL1 H3K27ac n = 2.
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Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | Genome-wide Hi-C analysis in T-ALL following γSI shows no intra-TAD activity differences, but individual promoter-enhancer 
loops are disrupted. a) Volcano plot showing differential intra-TAD activity between CUTLL1 DMSO vs CUTLL1 γSI (average activity > 0.58 / < -0.58 
and with FDR < 0.05). Statistical evaluation was performed using paired two-sided t test between all per bin-interactions between DMSO and γSI (n = 2 
replicates). b) Representation of TAD boundary alteration events (red dots; none identified). Plots depict pair-wise comparisons for TAD boundary 
losses of adjacent CUTLL1 (untreated, left) TADs and for TAD boundary gains of adjacent CUTLL1 (γSI treated, right) TADs. Dotted line represents 
outlier threshold as in Fig. 3 c) and d). c) Virtual 4 C of H3K27ac HiChIP in CUTLL1, using MYC promoter as viewpoint (chr8: 128,747,680), showing 
edgeR-normalized CPM. H3K27ac ChIP-seq track for MYC locus shown as fold-enrichment over input. Detected significant loops as arc-representation 
(below) from mango pipeline utilizing two-sided binomial test per matrix-diagonal followed by multiple testing correction66 (FDR < 0.1; CPM > 5). Number 
replicates: CUTLL1 H3K27ac HiChIP n = 1; CUTLL1 H3K27ac ChIP-seq n = 2. d) H3K27ac signal (enrichment over input) (left), chromatin interaction of the 
highest peak by 4C-seq (center) for the interaction of LUNAR1 promoter with its upstream enhancer and LUNAR1 expression (right). All quantifications 
are normalized to the respective average T cell signal, shown in percent. Significance of differences was calculated using diffBind with edgeR-method (for 
H3K27ac ChIP-seq, FDR) and edgeR (for 4C-seq interactions and GRO-seq as P value and FDR respectively). Error bars indicate s.d.; center value indicates 
mean. Number replicates: CUTLL1 DMSO H3K27ac n = 2; CUTLL1 γSI H3K27ac n = 2; CUTLL1 DMSO 4 C n = 2; CUTLL1 γSI 4 C n = 2; CUTLL1 DMSO GRO-
seq n = 2; CUTLL1 γSI GRO-seq n = 2. e) H3K27ac signal (left), chromatin interaction of the highest peak by 4C-seq (center) for the interaction of APCDD1 
enhancer with the downstream APCDD1 promoter and APCDD1 expression (right). All quantifications are normalized to the respective average T cell 
signal, shown in percent. Significance of differences was calculated using diffBind with edgeR-method (for H3K27ac ChIP-seq, FDR) and edgeR (for 4C-
seq interactions and GRO-seq as P value and FDR respectively). Error bars indicate s.d.; center value indicates mean. Number replicates: CUTLL1 DMSO 
H3K27ac n = 2; CUTLL1 γSI H3K27ac n = 2; CUTLL1 DMSO 4 C n = 2; CUTLL1 γSI 4 C n = 2; CUTLL1 DMSO GRO-seq n = 2; CUTLL1 γSI GRO-seq n = 2.  
f) Schematic of γSI sensitive and insensitive enhancer. g) Peak width of stable (black; n = 111) or decreased H3K27ac signal (green, n = 76) as defined in 
Fig. 5a. Significant difference between the distributions is estimated by a two-sided Wilcoxon test. Number replicates: CUTLL1 DMSO H3K27ac n = 2; 
CUTLL1 γSI H3K27ac n = 2.
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Extended Data Fig. 9 | See next page for caption.
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Extended Data Fig. 9 | Treatment with γSI does not alter all NOTCH1 dynamic enhancers. a) 4C-seq using MYC promoter as viewpoint. Positive y-axis 
shows interactions with viewpoint as normalized read counts, negative y-axis shows significance of differential interactions as log10(P value) calculated 
using edgeR function glmQLFTest (CUTLL1 DMSO n = 5; CUTLL1 γSI n = 3). Tracks below show H3K27ac, NOTCH1 ChIP-seq and GRO-seq (positive strand 
only) as fold-enrichment where applicable, and counts-per-million reads otherwise. Grey areas indicate MYC super-enhancer elements. b) Quantification 
of H3K27ac signal (enrichment over input), chromatin interactions by 4C-seq for the interactions of MYC promoter and MYC expression. Interaction 
changes are measured by centering the 40 kb bin on highest peaks within N-Me/NDME, CEE or BDME/BENC elements. MYC expression was measured 
by qPCR. All quantifications are normalized to CUTLL1 DMSO, shown in percent. Error bars indicate s.d.; center value indicates mean. Significance is 
shown as false-discovery rate (FDR) for H3K72ac signal change (R package DiffBind with edgeR-method), P value for chromatin interaction change (edgeR 
function glmQLFTest) or one-tailored t test for qPCR changes. c) Cropped western blot images immunoblotted with MYC antibody. Unprocessed western 
blots can be found as Source Data. Experiment was repeated twice with similar results. d) CTCF ChIP-qPCR of lost MYC boundary upon γSI in CUTLL1 
(n = 3). Error bars indicate s.d.; center value indicates mean. Significance was calculated using unpaired two-sided t test. e) 4C-seq analysis using IKZF2 
promoter as viewpoint after γSI treatment. Positive y-axis shows normalized read counts, negative y-axis shows significance of differential interactions  
as log10(P value) calculated using edgeR function glmQLFTest (CUTLL1 DMSO n = 3; CUTLL1 γSI n = 3). Tracks below show H3K27ac, NOTCH1  
ChIP-seq and GRO-seq (negative strand only) as fold-enrichment over input where applicable, and counts-per-million reads otherwise. Grey area indicates 
IKZF2 enhancer. f) H3K27ac signal is specific for enhancer highlighted in d). Interaction changes are measured by centering the 40 kb bin on the highest 
enhancer peak. IKZF2 expression after γSI treatment was measured by GRO-seq. All quantifications are normalized to the average T cell signal, shown in 
percent. Error bars indicate s.d.; center value indicates mean. Significance is shown as false-discovery rate (FDR) for H3K72ac signal (R package DiffBind 
with edgeR-method), P value for chromatin interaction (edgeR function glmQLFTest) or one-tailored t test for qPCR expression.
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Extended Data Fig. 10 | See next page for caption.
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Extended Data Fig. 10 | Treatment of T-ALL with THZ1 reduces also γSI insensitive promoter-enhancer interactions. a) H3K27ac signal is specific for 
N-Me/NDME, CEE and BDME/BENC. Interaction changes are measured by centering the 40 kb bin on highest peaks within N-Me/NDME, CEE or BDME/
BENC elements. MYC expression after THZ1 treatment was measured by qPCR. All quantifications are normalized to the average CUTLL1 DMSO signal, 
shown in percent. Error bars indicate s.d.; center value indicates mean. Significance is shown as false-discovery rate (FDR) for H3K72ac signal (R package 
DiffBind with edgeR-method), P value for chromatin interaction (edgeR function glmQLFTest) or two-sided t test for qPCR expression. b) Cropped western 
blot images immunoblotted with MYC antibody. Unprocessed western blots can be found as Source Data. Experiment was repeated twice with similar 
results. c) CTCF ChIP-qPCR, shown as enrichment over input, of CTCF site in lost boundary in MYC locus (n = 3). Error bars indicate s.d.; center value 
indicates mean. Significance was calculated using unpaired two-sided t test. d) Inter-probe distance between MYC promoter and MYC-CCE measured 
by DNA-FISH analysis. Statistical difference between distributions of probe distances was calculated using two-sample one-sided Kolmogorov Smirnov 
test. Error bars indicate s.d.; center value indicates median. Probe-pairs CUTLL1 DMSO = 2001. Probe-pairs CUTLL1 THZ1 = 1308. Median distance 
CUTLL1 DMSO = 264.28 µm. Median distance CUTLL1 THZ1 = 321.69 µm. e) 4C-seq using MYC promoter as viewpoint in Jurkat cells. Positive y-axis 
shows normalized interaction strength with the viewpoint, negative y-axis shows significance of differential interactions as log10(P value) calculated 
using edgeR function glmQLFTest (n = 3). Grey areas indicate MYC super-enhancer elements. f) Interaction changes are measured by centering the 
40 kb bin on N-Me/NDME, CEE or the BDME/BENC. Error bars indicate s.d.; center value indicates mean. Significance is shown as P value for chromatin 
interaction changes (edgeR function glmQLFTest). g) Quantification of changes in H3K27ac signal (enrichment over input) and chromatin interactions 
of IKZF2 enhancer in CUTLL1. All quantifications are normalized to the average CUTLL1 DMSO signal, shown in percent. Error bars indicate s.d.; center 
value indicates mean. Significance is shown as false-discovery rate (FDR) for H3K72ac signal change (R package DiffBind with edgeR-method), P value for 
chromatin interaction change (edgeR function glmQLFTest).
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Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency 
in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection All NCBI GEO datasets listed in Supplementary Table 2 were downloaded using sra toolkit version 2.8.0. 
RNA-Seq data from Chen et al. (see Supplementary Table 2) was downloaded via FTP from data owner upon request.
Data analysis bowtie2 version 2.3.1. Hi-C bench. genomic-tools. R version 3.3.0. ICE-normaliztion according to Imakeav et al.. TAD calling by hic-ratio. 
MACS2 version 2.0.1. bedtools version 2.27.1. diffBind version 2.2.12. IGV version 2.3.83. PWMScan. deeptools version 2.3.3. STAR-
aligner version 2.5.0c. ngsutils version 0.5.7. edgeR version 3.14.0. bowtie version 1.0.0. ROSE version 2015. picard-tools version XX. 
HiCnv.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
All sequencing data created within this study was uploaded to NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/) and is available under the accession GSE115896.
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Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size No prior sample size determination was conducted. All experiments were conducted in at least 2 biological replicates. Statistical testing 
ensured significant findings.
Data exclusions No replicates were excluded, and all attempts to replicate were successful.
Replication All experiments were conducted in at least 2 biological replicates. For all sequencing data-types, successful replication has been confirmed 
with Principal Component Analysis.
Randomization Randomization was relevant to the study, because the difference between healthy and disease was assessed.
Blinding The investigators were not blinded to sample group allocation, because the difference between healthy and disease was assessed. Sample 
group assignments were further ensured using Principal Component Analysis on all relevant sequencing data.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Antibodies
Antibodies used CTCF (D31H2; Cell Signaling Catalog no: 3418; lot 3 &4); H3K27ac (Active motif; Catalog no: 39133, Lot no: 01518010); c-MYC 
(D84C12; Cell Signaling; Catalog no: 5605, dilution 1:500) Lot no: 15; Actin (Millipore, clone C4, Catalog no: MAB1501R, Lot no: 
2819194, dilution 1:3000)
Validation Validation of antibodies is ensured by commercial manufacture for the application used.  
For CTCF antibody from Cell Signaling, the datasheet for validation is available at https://media.cellsignal.com/pdf/3418.pdf  
For H3K27ac antibody from Active motif, the datasheet for validation is available at https://www.activemotif.com/documents/
tds/39133.pdf 
For, C-MYC, the validation is available in https://media.cellsignal.com/pdf/14819.pdf 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) The CUTLL1 and Jurkat cell lines were a gift from Adolfo Ferrando's lab at Columbia.
Authentication Cell lines have been authenticated by PCR detection of originally described translocations, detection of intra-nuclear NOTCH1 
and sensitivity to originally described drugs
Mycoplasma contamination Cell lines were tested negative for mycoplasma.
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Commonly misidentified lines
(See ICLAC register)
The cell lines used in this study are not listed on the ICLAC list of commonly misidentified cell lines.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals NOD-SCID-Il2rg−/− (NSG) mice between 4 to 8 weeks age
Wild animals This study did not include wild animals.
Field-collected samples This study did not include field-collected samples.
Ethics oversight All animal experiments were performed in accordance with protocols approved by the New York University Institutional Animal 
Care and Use Committee.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics Additional co-variates (age, gender, diagnosis, mutational status) are listed in Supplementary Information.
Recruitment Healthy T cells have been ordered commercially. Leukemia samples have been selected for two specific sub-types but potential 
biases are discussed in Figure 1 and Supplementary Information combining mutation status, expression and chromatin 
interaction information.
Ethics oversight Samples were collected by Columbia Presbyterian Hospital or Weill Cornell Medical College with informed consent and approved 
and analyzed under the supervision of the Columbia University Medical Center Institutional Review Board or Weill Cornell 
Medical College Institutional Review Board.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
ChIP-seq
Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links 
May remain private before publication.
ChIP-Seq data was deposited at NCBI GEO under accession GSE115893. Token: ujmpiasozxstlwx  
https://urldefense.proofpoint.com/v2/url?
u=https-3A__www.ncbi.nlm.nih.gov_geo_query_acc.cgi-3Facc-3DGSE115893&d=DwIBAg&c=j5oPpO0eBH1iio48DtsedbOBG
muw5jHLjgvtN2r4ehE&r=N0slyiNu-4hMYPy11ZY72eU4uF0KhiHRWO11zlklvq8&m=Iy2Owf8yNQMY1mdVP20o-
vxkH3kmKtebTIULDAOM4kI&s=rAFpbkcjssrbSbe1AcbHad26xqxTtHhbyUuhv5reIf8&e= 
Files in database submission T cell CTCF rep1 
T cell CTCF rep2 
T-ALL1 CTCF rep1 
T-ALL1 CTCF rep2 
T-ALL2 CTCF rep1 
T-ALL2 input 
Jurkat CTCF rep1 
Jurkat CTCF rep2 
Jurkat input 
CUTLL1 CTCF rep1 
CUTLL1 CTCF rep2 
CUTLL1 CTCF rep3 
CUTLL1 CTCF rep4 
CUTLL1 CTCF rep5 
CUTLL1 H3K27ac rep1 
CUTLL1 H3K27ac rep2 
CUTLL1 H3K27ac rep3 
CUTLL1 H3K27ac rep4 
CUTLL1 gSI H3K27ac rep1 
CUTLL1 gSI H3K27ac rep2 
CUTLL1 THZ1 H3K27ac rep1 
CUTLL1 THZ1 H3K27ac rep2 
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Genome browser session 
(e.g. UCSC)
Bigwig tracks available through GEO.
Methodology
Replicates CTCF: 
T cells 2 replicates + 1 input 
T-ALL 1 as 2 replicates + 1 input 
T-ALL 2 as 1 replicates + 1 input 
CUTLL1 DMSO as 5 replicates + 1 input 
CUTLL1 gSI as 3 replicates + 1 input 
Jurkat as 2 replicates + 1 input 
 
H3K27ac: 
CUTLL1 DMSO as 2 replicates + 1 input 
CUTLL1 gSI as 2 replicates + 1 input 
CUTLL1 THZ1 as 2 replicates + 1 input
Sequencing depth Sequencing depth is detailed in Supplementary Table 1.
Antibodies CTCF (D31H2; Catalog no: 3418, lot 3 and 4); Lot no:; 10 ug antibody used per IP 
H3K27ac (Active motif; Catalog no: 39133) ; Lot no: Lot no: 01518010, 5ug antibody used per IP
Peak calling parameters MACS2 parameters for CTCF: --nomodel --extsize=200 --qvalue 0.05 
MACS2 parameters for H3K27ac: --broad --nomodel --extsize=200 --qvalue 0.05 --broad-cutoff 0.05 
 
using -c option to specify input samples
Data quality Based on merged peaks and peak strength, we performed Principal Component Analysis to ensure replication. 
Total number of peaks detected with above peak-calling approach: 
T cells CTCF: 34443 
T-ALL 1 CTCF: 28730 
T-ALL 2 CTCF: 64059 
CUTLL1 CTCF: 25213 
CUTLL1 gSI CTCF: 18111 
Jurkat CTCF: 15196 
CUTLL1 H3K27ac: 30726 
CUTLL1 gSI H3K27ac: 25309 
CUTLL1 THZ1 H3K27ac: 30542
Software Read alignment: Reads were aligned against the reference sequence hg19 with bowtie2 (version 2.3.1) with standard 
parameters and only uniquely mapped reads were kept with MAPQ > 20. 
Deduplication: Aligned reads were filtered for duplicated reads using picard-tools version 2.6.0. 
Peak-calling: Peak calling for CTCF and H3K27ac was performed using MACS2 (version 2.0.1) using narrow (CTCF) and broad 
(--broad; H3K27ac) option (sepcial parameters: --no-model). 
Differential binding: To identify differentially bound peaks, we performed diffBind (version 2.2.12) analysis, using the 
normalization option DBA_EDGER. 
Bigwig: For visualization purposes, we generated fold-enrichment bigwig files by applying MACS2 (version 2.0.1) bdgcmp 
over input (-m FE)
